Biocartis : Creates New Warrant Plan

PRESS RELEASE

REGULATED INFORMATION

Tuesday, 11 September 2018, 07:00 CEST

Biocartis Creates New Warrant Plan

Mechelen, Belgium, 11 September 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART) announces today that its board of directors created, within the framework of the authorized capital, 1,335,426 warrants under a new warrant plan, called the 'Warrant Plan 2018', in order to enable the Company to offer the warrants to mainly certain selected employees of the Company and its subsidiaries, as well as to consultants of the Company and its subsidiaries, independent directors of the Company and directors of the Company's subsidiaries.

The warrants under the Warrant Plan 2018 have an exercise term of ten years (unless contractually reduced in the offer to a beneficiary), are generally not transferable and can in principle not be exercised prior to the first day of the fourth calendar year following the calendar year in which the offer of warrants is accepted by a beneficiary. Each warrant gives the right to subscribe to one new Biocartis share. Should the warrants be exercised, Biocartis will apply for the admission to trading of the resulting new shares on Euronext Brussels. The warrants as such will not be listed on any stock market.

The special reports prepared by the board of directors (in accordance with Articles 583, 596 and 598 of the Belgian Companies Code) and the Company's statutory auditor (in accordance with Articles 596 and 598 of the Belgian Companies Code) in the framework of the creation of the Warrant Plan 2018 can be consulted on thewebsite ofthe Company.

--- END ---

More information:

Renate Degrave

Manager Corporate Communications & Investor Relations [e-mail] tel [phone] mobile [phone]

@Biocartis_

www.linkedin.com/Biocartis

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla™ platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers fifteen oncology tests and two infectious disease tests in Europe. More information:www.biocartis.com. Press Photo Library availablehere.Follow us onTwitter:@Biocartis_.

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. Biocartis trademark and logo and Idylla™ trademark and logo are used trademarks belonging to Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements.